News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
267,511 Results
Type
Article (14269)
Company Profile (284)
Press Release (252958)
Section
Business (80483)
Career Advice (155)
Deals (13410)
Drug Delivery (35)
Drug Development (50633)
Employer Resources (31)
FDA (5817)
Job Trends (5203)
News (145937)
Policy (10157)
Tag
Academia (950)
Alliances (21825)
Alzheimer's disease (790)
Antibody-drug conjugate (ADC) (70)
Approvals (5804)
Artificial intelligence (91)
Bankruptcy (101)
Best Places to Work (4616)
Biotechnology (232)
Breast cancer (123)
Cancer (1049)
Cardiovascular disease (84)
Career advice (135)
CAR-T (86)
Cell therapy (248)
Clinical research (40653)
Collaboration (403)
Compensation (156)
COVID-19 (1029)
C-suite (104)
Cystic fibrosis (73)
Data (1080)
Diabetes (99)
Diagnostics (1272)
Earnings (29486)
Events (48262)
Executive appointments (329)
FDA (6271)
Funding (390)
Gene editing (73)
Gene therapy (190)
GLP-1 (341)
Government (1087)
Healthcare (6777)
Infectious disease (1072)
Inflammatory bowel disease (100)
IPO (7307)
Job creations (878)
Job search strategy (129)
Layoffs (197)
Legal (1417)
Lung cancer (156)
Manufacturing (95)
Medical device (2677)
Medtech (2678)
Mergers & acquisitions (6314)
Metabolic disorders (302)
Neuroscience (1087)
NextGen: Class of 2025 (2064)
Non-profit (910)
Northern California (1259)
Obesity (162)
Opinion (94)
Parkinson's disease (88)
Patents (72)
People (25613)
Phase I (14313)
Phase II (18894)
Phase III (11988)
Pipeline (465)
Postmarket research (863)
Preclinical (6001)
Radiopharmaceuticals (209)
Rare diseases (234)
Real estate (1453)
Regulatory (8470)
Research institute (985)
Series A (75)
Southern California (1121)
Startups (1983)
United States (9973)
Vaccines (183)
Weight loss (95)
Date
Today (65)
Last 7 days (367)
Last 30 days (1631)
Last 365 days (20611)
2025 (1684)
2024 (20722)
2023 (22604)
2022 (27054)
2021 (28124)
2020 (23667)
2019 (16586)
2018 (12044)
2017 (13932)
2016 (12012)
2015 (14638)
2014 (10607)
2013 (7614)
2012 (7673)
2011 (7755)
2010 (7523)
Location
Africa (149)
Asia (17253)
Australia (2912)
California (2860)
Canada (904)
China (255)
Colorado (108)
Connecticut (118)
Delaware (69)
Europe (37295)
Florida (326)
Georgia (84)
Illinois (187)
Indiana (72)
Maryland (374)
Massachusetts (2265)
Minnesota (121)
New Jersey (715)
New York (795)
North Carolina (455)
Northern California (1259)
Ohio (91)
Pennsylvania (542)
South America (245)
Southern California (1121)
Texas (318)
Washington State (277)
267,511 Results for "monte rosa therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Collaboration
Novartis Inks Potential $2.2B Molecular Glue Deal With Monte Rosa
The Swiss pharma is paying $150 million upfront to gain rights to Monte Rosa’s VAV1-targeting molecular glue degraders, led by a Phase I candidate which holds therapeutic promise for immune-mediated diseases.
October 28, 2024
·
2 min read
·
Tristan Manalac
Press Releases
Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2025
January 13, 2025
·
14 min read
Press Releases
Monte Rosa Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
January 6, 2025
·
1 min read
Press Releases
Monte Rosa Therapeutics to Participate in the Piper Sandler Healthcare Conference
November 27, 2024
·
1 min read
Press Releases
Monte Rosa Therapeutics Appoints Dr. Eric A. Hughes to Board of Directors
December 13, 2024
·
3 min read
Press Releases
Monte Rosa Therapeutics to Participate in the Jefferies London Healthcare Conference
November 13, 2024
·
1 min read
Business
Monte Rosa Therapeutics Announces Leadership Team Promotions
Monte Rosa Therapeutics, Inc. today announced three leadership team promotions effective immediately: Sharon Townson, Ph.D., to Chief Scientific Officer; Phil Nickson, Ph.D., J.D., to Chief Business and Legal Officer; and Jennifer Champoux to Chief Operating Officer.
May 30, 2024
·
3 min read
Genetown
Monte Rosa Therapeutics to Present at the Jefferies Global Healthcare Conference
Monte Rosa Therapeutics, Inc. today announced that Markus Warmuth, M.D., Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024, at 3:30 p.m. ET.
May 30, 2024
·
1 min read
Deals
Monte Rosa Therapeutics Announces Pricing of $100 Million Underwritten Public Offering
Monte Rosa Therapeutics, Inc. today announced the pricing of an underwritten public offering of 10,638,476 shares of its common stock at a public offering price of $4.70 per share.
May 16, 2024
·
5 min read
Genetown
Monte Rosa Therapeutics Provides Development Progress Updates on MRT-2359 and MRT-6160
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company developing novel molecular glue degrader -based medicines, announced progress updates for its two lead programs, MRT-2359, an MGD being developed for MYC-driven solid tumors, and MRT-6160, a VAV1-directed MGD in development for systemic and neurological autoimmune diseases.
June 27, 2024
·
9 min read
1 of 26,752
Next
